These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 10823378)

  • 1. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.
    MacDonald A; Scarola J; Burke JT; Zimmerman JJ
    Clin Ther; 2000; 22 Suppl B():B101-121. PubMed ID: 10823378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB; Grimm EM
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus: the evidence for clinical pharmacokinetic monitoring.
    Stenton SB; Partovi N; Ensom MH
    Clin Pharmacokinet; 2005; 44(8):769-86. PubMed ID: 16029064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.
    Goyal RK; Han K; Wall DA; Pulsipher MA; Bunin N; Grupp SA; Mada SR; Venkataramanan R
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):569-75. PubMed ID: 23266742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus: a new agent for prevention of renal allograft rejection.
    Vasquez EM
    Am J Health Syst Pharm; 2000 Mar; 57(5):437-48; quiz 449-51. PubMed ID: 10711524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
    Kovarik JM
    Drugs Today (Barc); 2004 Feb; 40(2):101-9. PubMed ID: 15045032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the proliferation inhibitor everolimus.
    Nashan B
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1845-57. PubMed ID: 12457444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of sirolimus.
    Mahalati K; Kahan BD
    Clin Pharmacokinet; 2001; 40(8):573-85. PubMed ID: 11523724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological surrogates of allograft outcome.
    Mahalati K; Kahan BD
    Ann Transplant; 2000; 5(2):14-23. PubMed ID: 11217202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
    Tsai MK; Chueh SC; Hu RH; Lee PH
    J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts.
    Reichen J; Stickel F; Bhattacharya I; Matschke K; Maller E; Korth-Bradley J
    Eur J Clin Pharmacol; 2012 May; 68(5):589-97. PubMed ID: 22143911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.
    Monchaud C; Marquet P
    Clin Pharmacokinet; 2009; 48(7):419-62. PubMed ID: 19691367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
    Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Level of evidence for therapeutic drug monitoring of everolimus].
    Goirand F; Royer B; Hulin A; Saint-Marcoux F;
    Therapie; 2011; 66(1):57-61. PubMed ID: 21466779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
    Żochowska D; Wyzgał J; Pączek L
    Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.